UniQure Says FDA Clears IND Application For AMT-191 Gene Therapy For Fabry Disease
Gene therapy company uniQure N.V. (QURE) announced Wednesday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AMT-191, the Company's gene therapy candidate for Fabry disease.
United States Drug Administration Investigational New Drug Us Food And Drug Administration Fabry Disease Ene Therapy Company Uniqure
Source: rttnews.com